166 related articles for article (PubMed ID: 20371443)
21. Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN).
Dimopoulos MA; García-Sanz R; Gavriatopoulou M; Morel P; Kyrtsonis MC; Michalis E; Kartasis Z; Leleu X; Palladini G; Tedeschi A; Gika D; Merlini G; Kastritis E; Sonneveld P
Blood; 2013 Nov; 122(19):3276-82. PubMed ID: 24004667
[TBL] [Abstract][Full Text] [Related]
22. Bortezomib-Dexamethasone, Rituximab, and Cyclophosphamide as First-Line Treatment for Waldenström's Macroglobulinemia: A Prospectively Randomized Trial of the European Consortium for Waldenström's Macroglobulinemia.
Buske C; Dimopoulos MA; Grunenberg A; Kastritis E; Tomowiak C; Mahé B; Troussard X; Hajek R; Viardot A; Tournilhac O; Aurran T; Lepretre S; Zerazhi H; Hivert B; Leblond V; de Guibert S; Brandefors L; Garcia-Sanz R; Gomes da Silva M; Kimby E; Schmelzle B; Kaszynski D; Dreyhaupt J; Muche R; Morel P
J Clin Oncol; 2023 May; 41(14):2607-2616. PubMed ID: 36763945
[TBL] [Abstract][Full Text] [Related]
23. Interplay between proteasome inhibitors and NF-κB pathway in leukemia and lymphoma: a comprehensive review on challenges ahead of proteasome inhibitors.
Pakjoo M; Ahmadi SE; Zahedi M; Jaafari N; Khademi R; Amini A; Safa M
Cell Commun Signal; 2024 Feb; 22(1):105. PubMed ID: 38331801
[TBL] [Abstract][Full Text] [Related]
24. Bortezomib potentiates antitumor activity of mitoxantrone through dampening Wnt/β-catenin signal pathway in prostate cancer cells.
Zhang Y; Liu Q; Wei W; Zhang G; Yan S; Dai R; Sun Y; Su D; Lv S; Xia Y; Li J; Li C
BMC Cancer; 2021 Oct; 21(1):1101. PubMed ID: 34645397
[TBL] [Abstract][Full Text] [Related]
25. Phase I/II trial of everolimus in combination with bortezomib and rituximab (RVR) in relapsed/refractory Waldenstrom macroglobulinemia.
Ghobrial IM; Redd R; Armand P; Banwait R; Boswell E; Chuma S; Huynh D; Sacco A; Roccaro AM; Perilla-Glen A; Noonan K; MacNabb M; Leblebjian H; Warren D; Henrick P; Castillo JJ; Richardson PG; Matous J; Weller E; Treon SP
Leukemia; 2015 Dec; 29(12):2338-46. PubMed ID: 26139427
[TBL] [Abstract][Full Text] [Related]
26. Overcoming bortezomib resistance in human B cells by anti-CD20/rituximab-mediated complement-dependent cytotoxicity and epoxyketone-based irreversible proteasome inhibitors.
Verbrugge SE; Al M; Assaraf YG; Niewerth D; van Meerloo J; Cloos J; van der Veer M; Scheffer GL; Peters GJ; Chan ET; Anderl JL; Kirk CJ; Zweegman S; Dijkmans BA; Lems WF; Scheper RJ; de Gruijl TD; Jansen G
Exp Hematol Oncol; 2013 Jan; 2(1):2. PubMed ID: 23305345
[TBL] [Abstract][Full Text] [Related]
27. Successful treatment of cryoglobulinemic glomerulonephritis derived from Waldenström's macroglobulinemia by rituximab-CHOP and tandem high-dose chemotherapy with autologous peripheral blood stem cell transplantation.
Kawano N; Ikeda N; Yoshida S; Sugio Y; Yamashita K; Uezono S; Hayashi T; Hara S; Makino S; Shimoda K; Ueda A
Int J Hematol; 2010 Sep; 92(2):391-7. PubMed ID: 20686877
[TBL] [Abstract][Full Text] [Related]
28. Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia.
Dimopoulos MA; Gertz MA; Kastritis E; Garcia-Sanz R; Kimby EK; Leblond V; Fermand JP; Merlini G; Morel P; Morra E; Ocio EM; Owen R; Ghobrial IM; Seymour J; Kyle RA; Treon SP
J Clin Oncol; 2009 Jan; 27(1):120-6. PubMed ID: 19047284
[TBL] [Abstract][Full Text] [Related]
29. [Waldenström's macroglobulinemia].
Poulain S; Wemeau M; Balkaran S; Hivert B; Hautecoeur A; Rossignol J; Fernandez J; Daudignon A; Roumier C; Soenen V; Lepelley P; Lai JL; Morel P; Leleu X
Rev Med Interne; 2010 May; 31(5):385-94. PubMed ID: 20363537
[TBL] [Abstract][Full Text] [Related]
30. Bortezomib in relapsed or refractory Waldenström's macroglobulinemia.
Chen C; Kouroukis CT; White D; Voralia M; Stadtmauer E; Stewart AK; Wright JJ; Powers J; Walsh W; Eisenhauer E
Clin Lymphoma Myeloma; 2009 Mar; 9(1):74-6. PubMed ID: 19362979
[TBL] [Abstract][Full Text] [Related]
31. Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group.
Chen CI; Kouroukis CT; White D; Voralia M; Stadtmauer E; Stewart AK; Wright JJ; Powers J; Walsh W; Eisenhauer E;
J Clin Oncol; 2007 Apr; 25(12):1570-5. PubMed ID: 17353550
[TBL] [Abstract][Full Text] [Related]
32. Bortezomib and Waldenstrom's macroglobulinemia.
Pascal L; Gay J; Willekens C; Wemeau M; Balkaran S; Robu D; Roccaro A; Morel P; Ghobrial I; Leleu X
Expert Opin Pharmacother; 2009 Apr; 10(5):909-16. PubMed ID: 19351237
[TBL] [Abstract][Full Text] [Related]
33. Bortezomib as a treatment option in patients with Waldenström macroglobulinemia.
Dimopoulos MA; Chen C; Kastritis E; Gavriatopoulou M; Treon SP
Clin Lymphoma Myeloma Leuk; 2010 Apr; 10(2):110-7. PubMed ID: 20371443
[TBL] [Abstract][Full Text] [Related]
34.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
